---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-039286"
form_type: "8-K"
ticker: "ATOS"
cik: "0001488039"
company_name: "ATOSSA THERAPEUTICS, INC."
filed_at: "2024-04-01T23:59:59+00:00"
generated_at: "2026-06-04T04:30:59.728551+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Atossa ends FY2023 with $88.5M cash; two Phase 2 studies fully enrolled, data due H2 2024

## Summary
- Cash and equivalents $88.5M as of Dec 31, 2023; no debt outstanding.
- Operating expenses $31.4M in 2023, up $3.7M from $27.7M in 2022.
- Phase 2 Karisma-Endoxifen (breast density) fully enrolled Nov 2023; top-line data expected H2 2024.
- Phase 2 I-SPY 2 (neoadjuvant breast cancer) fully enrolled Feb 2024; data expected H2 2024.
- First patient dosed in Phase 2 RECAST DCIS study; EVANGELINE data at AACR April 9, 2024.

## SEC filing metadata
- accession: 0000950170-24-039286
- form_type: 8-K
- ticker: ATOS
- cik: 0001488039
- company_name: ATOSSA THERAPEUTICS, INC.
- filed_at: 2024-04-01T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1488039/000095017024039286/0000950170-24-039286-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1488039/000095017024039286/atos-20240401.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-039286
- JSON: https://secwatch.observer/filing/0000950170-24-039286.json
- Plain text: https://secwatch.observer/filing/0000950170-24-039286.txt

## Key facts
- Earnings Releases
  ATOSSA THERAPEUTICS, INC. reported financial results for the year ended December 31, 2023.
  - Period: the year ended December 31, 2023
  - Result: reported results
  source text: Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), today announced financial results for the forth quarter and full year ended December 31, 2023, and provided an update on recent Company developments.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1488039/000095017024039286/0000950170-24-039286-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.